Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC)

7061 Background: Amrubicin, a totally synthetic 9-amino-anthracycline, has been shown to have excellent antitumor activity as a single agent against previously untreated extensive-stage SCLC. The o...